Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62021 | 0.84 | POLB (0.53) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL537673 | 0.84 | MAPK1 (0.42) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL28715240 | 0.81 | MAPK1 (0.41) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL29352953 | 0.81 | MAPK1 (0.41) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL10389212 | 0.81 | MAPK1 (0.41) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL10389241 | 0.81 | MAPK1 (0.41) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL1271823 | 0.78 | POLB (0.39) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL1598214 | 0.76 | KMT2A (0.49) | KMT2AMEN1GAAPOLBHTT | |
| SCHEMBL1902046 | 0.76 | POLB (0.47) | KMT2AMEN1GAASMN1; SMN2POLB | |
| SCHEMBL19805989 | 0.74 | POLB (0.46) | KMT2AMEN1GAASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12157737-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2024-12-03 | — | — | US | disclosed |
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2024-02-08 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11685740-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| US-11685740-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| CN-116157404-A | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | 诺华股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-6562970-B1 | Method for producing 4-chloro-6-hydroxypyrimidine | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| EP-1194413-A1 | METHOD FOR PRODUCING 4-CHLORO-6-HYDROXYPYRIMIDINE | Bayer Aktiengesellschaft (DE) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001000593-A1 | METHOD FOR PRODUCING 4-CHLORO-6-HYDROXYPYRIMIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000046212-A1 | METHOD OF PRODUCING SUBSTITUTED PYRIMIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-08-10 | — | — | WO | disclosed |
| EP-0468069-B1 | Process for producing a 4,6-bis(difluoromethoxy)-2-alkylthiopyrimidine | ASAHI GLASS CO LTD (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0244359-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-07-22 | — | — | EP | disclosed |
| EP-0468069-A1 | Process for producing a 4,6-bis(difluoromethoxy)-2-alkylthiopyrimidine | ASAHI GLASS COMPANY LTD. (JP) | 1992-01-29 | — | — | EP | disclosed |
| US-5071982-A | Process for producing a 4,6-bis(difluoromethoxy)-2-alkylthiopyrimidine | ASAHI GLASS CO., LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0244359-A2 | Process for the preparation of pyrimidine derivatives | CIBA-GEIGY AG (CH) | 1987-11-04 | — | — | EP | disclosed |
| US-4692524-A | HERBICIDE INTERMEDIATES | CIBA-GEIGY CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157737-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | KMT2A 3399/4885MEN1 1544/4885GAA 2599/4885 |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | KMT2A 3399/4885MEN1 1544/4885GAA 2599/4885 |
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | KMT2A 3399/4885MEN1 1544/4885GAA 2599/4885 |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, PKD1, PKD2 | KMT2A 2996/4885MEN1 1485/4885GAA 2233/4885 |
| US-11685740-B2 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | P2RX7, P2RX2, P2RX1 | KMT2A 2254/4885MEN1 2921/4885GAA 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.